文献速递冠心病

急性心肌梗死患者的再灌注损伤:JACC科学声明

Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

该科学声明聚焦ST段抬高型心肌梗死患者再灌注治疗中的心肌缺血-再灌注损伤问题。文章阐述了活性氧、炎症、钙超载、内皮功能障碍及微血管血流受损等病理分子机制,并综述了临床前及临床研究中前景较好的药物策略和再灌注前机械卸载等新方法。

要点

  • STEMI再灌注虽必要,但血流突然恢复可触发进一步坏死。
  • 缺血-再灌注损伤机制涉及活性氧、炎症、钙超载及微血管障碍。
  • 再灌注前机械卸载等新策略正在临床试验中评估。

核心结论

  • 再灌注是心肌挽救的必要条件,但血流突然恢复可触发损伤级联导致进一步坏死,即心肌缺血-再灌注损伤。

主要发现

  • 心肌缺血-再灌注损伤的病理和分子基础包括活性氧损伤、炎症、钙超载、内皮功能障碍及微血管血流受损。

临床怎么用

  • 多种药物策略在临床前模型中有效,部分在临床环境中显示前景。
  • 再灌注前机械卸载心脏等新机械方法正在临床试验中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite impressive improvements in the care of patients with ST-segment elevation myocardial infarction, mortality remains high. Reperfusion is necessary for myocardial salvage, but the abrupt return of flow sets off a cascade of injurious processes that can lead to further necrosis. This has been termed myocardial ischemia-reperfusion injury and is the subject of this review. The pathologic and molecular bases for myocardial ischemia-reperfusion injury are increasingly understood and include injury from reactive oxygen species, inflammation, calcium overload, endothelial dysfunction, and impaired microvascular flow. A variety of pharmacologic strategies have been developed that have worked well in preclinical models and some have shown promise in the clinical setting. In addition, there are newer mechanical approaches including mechanical unloading of the heart prior to reperfusion that are in current clinical trials.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Welt, Batchelor, Spears, et al. Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement. J Am Coll Cardiol. 2024. PMID: 38811097. doi:10.1016/j.jacc.2024.02.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。